Review Article
Towards Personalized Medicine Based on Platelet Function Testing for Stent Thrombosis Patients
Table 4
Overview on how to decide to optimize personalized medicine for P2Y12 inhibitors per patient.
| | |
Number of platelet function tests for P2Y12 inhibitor that shows | | | | | NPR | HPR | How is the patient treated with current APT? | What to do with the APT? |
|  | 3 | 0 | Well treated | Current APT can be continued | | 2 | 1 | Well treated | Current APT can be continued | | 1 | 2 | Undertreated | Switch APT; consider
(i) Clinical characteristics
(ii) Comedication
(iii) Genetics | | 0 | 3 | Undertreated | Switch APT; consider:
(i) Clinical characteristics
(ii) Comedication
(iii) Genetics |
|
|
NPR: normal on-treatment platelet reactivity; HPR: high on-treatment reactivity; APT: antiplatelet therapy.
|
